Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Protein and Peptide Letters
|
March 30, 2011
Protamines. Editorial
Monique Cosman Balhorn, Rod Balhorn
Oncotarget
|
September 16, 2020
Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers
Rod Balhorn, Monique Cosman Balhorn
Journal of Drug Targeting
|
June 27, 2020
The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers
Rod Balhorn, Monique Cosman Balhorn, Karuppiah Balakrishnan, et al.
Veterinary Immunology and Immunopathology
|
June 26, 2010
A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas
Rod L Balhorn, Katherine A Skorupski, Saphon Hok, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Protein and Peptide Letters
|
March 30, 2011
Protamines. Editorial
Monique Cosman Balhorn, Rod Balhorn
Oncotarget
|
September 16, 2020
Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers
Rod Balhorn, Monique Cosman Balhorn
Journal of Drug Targeting
|
June 27, 2020
The small molecule antibody mimic SH7139 targets a family of HLA-DRs expressed by B-cell lymphomas and other solid cancers
Rod Balhorn, Monique Cosman Balhorn, Karuppiah Balakrishnan, et al.
Veterinary Immunology and Immunopathology
|
June 26, 2010
A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas
Rod L Balhorn, Katherine A Skorupski, Saphon Hok, et al.
Page
of 1